Safety and efficacy of immune checkpoint inhibitors in persons with HIV at a single, tertiary care cancer center in the United States

Résumé fourni par la source

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has demonstrated safety and efficacy in a variety of malignancies, including cancers affecting patients with HIV (PWH). However, there is limited data directly comparing outcomes of ICI use between cancer patients with versus without HIV. METHODS: Real-world retrospective data were used to compare clinical outcomes between 24 PWH and cancer and 24 matched cancer patients without HIV, all treated with ICI therapy at a large tertiary cancer center in Florida. RESULTS: Adverse event rates did not differ by HIV status. Overall response (complete or partial response) to ICI therapy was observed in 29% of PWH compared to 38% of people without HIV (PWoH), but this difference was not statistically significant. The overall survival at end of study follow-up by HIV status was similar between both groups (63% in PWH and 67% in PWoH). CONCLUSION: These findings suggest that HIV status alone should not preclude use of ICI therapy to improve prognosis among PWH and cancer.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.